Illumina Tells Investors Cancer Samples, Not Sequencing, Are Bottleneck in Dx Initiative

At the UBS Global Life Sciences Conference in New York last week, Illumina President and CEO Jay Flatley also said that the firm is "pleased with" the progress of Oxford Nanopore Technologies, in which it invested $18 million earlier this year.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.